Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma

Launched by ABBVIE · Feb 12, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called epcoritamab for adults with two types of blood cancer: diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). DLBCL is a fast-growing cancer, while FL is slower and generally less aggressive. The main goal of the trial is to see how well epcoritamab works in real-life settings for people who have already received other treatments for their cancer. About 700 participants from around 80 different locations in 12-20 countries will take part.

To be eligible for this trial, participants must be adults who are scheduled to receive epcoritamab after having had at least two previous treatments for their DLBCL or FL. Importantly, the decision to use this drug must have been made by their doctor before they were approached to join the study. Participants will not face extra demands; they will continue their regular visits to a hospital or clinic for monitoring over a period of up to three years. This study aims to gather valuable information while ensuring that participants receive the care they need.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Participants who are scheduled to be treated with epcoritamab for Treatment after two or more prior lines of therapy 3L+ diffuse large B-cell lymphoma ((D)LBCL) or 3L+ Follicular lymphoma (FL).
• • Treatment with epcoritamab should be administered in accordance with the approved local label in the participating country.
• • The decision to treat the participant should have been made by the clinician prior to, and independently of any decision to approach the participant to participate in this study.
• Exclusion Criteria:
• • Any condition included in the contraindications section of the approved local epcoritamab label in the participating country.
• • Participation in a concurrent interventional clinical trial (not including non-interventional/ observational study, PMOS, or registry participation) from enrollment and throughout the study.